Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

THE EFFECTS OF GAMBIR CATECHIN (UNCARIA GAMBIR ROXB) SUPPLEMENTATION ON COGNITIVE FUNCTION, EXPRESSION OF AMYLOID PRECURSOR PROTEIN (APP), MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT), BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF), INTERLEUKIN 10 (IL-10), TRANSFORMING GROWTH FACTOR-BETA (TGF-BETA), AND PLASMA MALONDIALDEHYDE (MDA) LEVELS IN THE ELDERLY

NCT06604390 is registered in ClinicalTrials.gov with Rahmi Novita Yusuf as lead sponsor.

NCT NCT06604390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06604390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
THE EFFECTS OF GAMBIR CATECHIN (UNCARIA GAMBIR ROXB) SUPPLEMENTATION ON COGNITIVE FUNCTION, EXPRESSION OF AMYLOID PRECURSOR PROTEIN (APP), MICROTUBULE ASSOCIATED PROTEIN TAU (MAPT), BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF), INTERLEUKIN 10 (IL-10), TRANSFORMING GROWTH FACTOR-BETA (TGF-BETA), AND PLASMA MALONDIALDEHYDE (MDA) LEVELS IN THE ELDERLY
Lead sponsor
Rahmi Novita Yusuf
Phase
Not applicable
Overall status
Completed
Start date
February 1, 2024
Completion date
August 15, 2024
Enrollment
64 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

elderly individuals aged 60 years or older, mild cognitive impairment (mci)